Incretin-Based Therapies

Incretin-based therapies are a group of medications that work by copying the action of natural gut hormones called incretins. These hormones tell your pancreas to release insulin, slow down digestion, and send fullness signals to your brain. The result is better blood sugar control, reduced appetite, and meaningful weight loss — which is why some of these medications have become breakthrough treatments for obesity.

Incretin-based therapies target the enteroinsular axis by either mimicking (GLP-1 receptor agonists such as semaglutide, liraglutide, and tirzepatide — a dual GLP-1/GIP receptor agonist) or prolonging the action of (DPP-4 inhibitors such as sitagliptin) endogenous incretin hormones. GLP-1 receptor agonists delay gastric emptying, promote satiety via hypothalamic and brainstem pathways, and enhance glucose-dependent insulin secretion. The dual and triple agonists — incorporating GIP and glucagon receptor agonism — represent the next frontier, with agents such as retatrutide demonstrating up to 24% total body weight loss in phase 2 trials.

Incretin-based therapies have transformed the medical management of obesity, offering weight loss approaching that of bariatric surgery in some cases. At Accord Medical, Dr. Joseph Wang can assess whether you are a candidate for these medications and guide you through a comprehensive programme combining pharmacotherapy with lifestyle and nutritional support.